pharmaphorum April 16, 2024
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its 139-year history.
The company expects to start around 10 new phase 2 and 3 trials within the next 12 to 18 months, supported by an R&D spend that reached €5.8 billion last year, a rise of 14% and accounting for 22.5% of net sales.
The current pipeline includes nearly 60 assets across 90 indications, said Boehringer’s head of innovation Dr Paola Casarosa, during an annual press conference this morning, with 70% of those programmes having an opportunity to offer first-in-class mechanisms.
She mentioned...
Today's Sponsors
Today's Sponsor